{"filing":{"accession_number":"0001650664-26-000082","cik":"0001650664","ticker":"EDIT","company_name":"Editas Medicine, Inc.","form":"8-K","filing_date":"2026-08-05","report_date":"2026-08-03","primary_document":"edit-20260803.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1650664/000165066426000082/edit-20260803.htm"},"events":[{"id":25194,"run_id":22860,"accession_number":"0001650664-26-000082","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Editas Medicine issued a press release on August 5, 2026 announcing financial results for the fiscal quarter ended June 30, 2026, including quarterly net loss of $18.2 million (versus $53.2 million in the prior year), revenue figures, operating expenses, cash position of $211.6 million, and business updates on the EDIT-401 program.","company_name":"Editas Medicine, Inc.","ticker":"EDIT","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":25954,"accession_number":"0001650664-26-000082","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Editas Medicine issued a press release on August 5, 2026 announcing financial results for the fiscal quarter ended June 30, 2026, including consolidated statements of operations and balance sheet items. The disclosure includes quarterly net loss ($18.2 million vs. $53.2 million prior year), revenue figures, operating expenses, and cash position ($211.6 million), along with business updates on the EDIT-401 program. This is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:18:17.874604+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":25195,"run_id":22860,"accession_number":"0001650664-26-000082","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"Patrick T. Ellinor, M.D., Ph.D., a recognized leader in cardiovascular medicine and human genetics, was appointed as an independent director effective August 6, 2026, with an annual cash compensation of $40,000 and an option grant of 103,400 shares.","company_name":"Editas Medicine, Inc.","ticker":"EDIT","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":25955,"accession_number":"0001650664-26-000082","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The Item 5.02 disclosure centers on the appointment of Patrick T. Ellinor, M.D., Ph.D. as an independent director effective August 6, 2026, following Elliott Levy's resignation. While both a departure and appointment occurred, the filing's substantive focus is on Dr. Ellinor's appointment, his qualifications as a recognized leader in cardiovascular medicine and human genetics, and his director compensation package (annual cash of $40,000 and an option grant of 103,400 shares). This is a material governance event affecting board composition at a public biotech company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:18:17.874604+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":25954,"accession_number":"0001650664-26-000082","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Editas Medicine issued a press release on August 5, 2026 announcing financial results for the fiscal quarter ended June 30, 2026, including consolidated statements of operations and balance sheet items. The disclosure includes quarterly net loss ($18.2 million vs. $53.2 million prior year), revenue figures, operating expenses, and cash position ($211.6 million), along with business updates on the EDIT-401 program. This is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:18:17.874604+00:00","company_name":"Editas Medicine, Inc.","ticker":"EDIT","filing_date":"2026-08-05"},{"id":25955,"accession_number":"0001650664-26-000082","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The Item 5.02 disclosure centers on the appointment of Patrick T. Ellinor, M.D., Ph.D. as an independent director effective August 6, 2026, following Elliott Levy's resignation. While both a departure and appointment occurred, the filing's substantive focus is on Dr. Ellinor's appointment, his qualifications as a recognized leader in cardiovascular medicine and human genetics, and his director compensation package (annual cash of $40,000 and an option grant of 103,400 shares). This is a material governance event affecting board composition at a public biotech company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:18:17.874604+00:00","company_name":"Editas Medicine, Inc.","ticker":"EDIT","filing_date":"2026-08-05"}]}